Avadel Pharmaceuticals (AVDL) Share-based Compensation (2016 - 2022)
Historic Share-based Compensation for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Q4 2022 value amounting to $1.9 million.
- Avadel Pharmaceuticals' Share-based Compensation fell 3078.3% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $7.0 million, marking a year-over-year decrease of 2095.36%. This contributed to the annual value of $20.4 million for FY2024, which is 2894.19% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Share-based Compensation of $1.9 million as of Q4 2022, which was down 3078.3% from $1.9 million recorded in Q3 2022.
- Avadel Pharmaceuticals' 5-year Share-based Compensation high stood at $2.8 million for Q3 2018, and its period low was -$229000.0 during Q3 2019.
- Over the past 5 years, Avadel Pharmaceuticals' median Share-based Compensation value was $1.5 million (recorded in 2020), while the average stood at $1.4 million.
- In the last 5 years, Avadel Pharmaceuticals' Share-based Compensation tumbled by 10808.62% in 2019 and then surged by 129818.18% in 2020.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Share-based Compensation stood at $662000.0 in 2018, then plummeted by 48.34% to $342000.0 in 2019, then soared by 278.36% to $1.3 million in 2020, then skyrocketed by 115.15% to $2.8 million in 2021, then crashed by 30.78% to $1.9 million in 2022.
- Its Share-based Compensation stands at $1.9 million for Q4 2022, versus $1.9 million for Q3 2022 and $658000.0 for Q2 2022.